Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.

Original reporting
Published Nov 12, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bearish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVAHBearishHigh
01

Why it matters

The modest guidance lift suggests limited growth momentum, prompting investors to sell, which may create a buying opportunity if the market overreacts.

02

Market read

Earnings beat with weak guidance leads to immediate price pressure; traders may act on the sell‑off.

03

What to watch

Strong cash flow generation and expanding margins may support longer‑term upside despite short‑term sell‑off.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Aveanna Healthcare (NASDAQ:AVAH) posted Q3 results that beat EPS and revenue estimates, yet its FY2026 guidance barely exceeded consensus, causing a pre‑market decline.

Company-level read

Ticker impact

$AVAHBearishHigh confidence
Context

Shares fell 6% in pre‑market after Aveanna Healthcare reported Q3 earnings beat but guidance that disappointed investors.

Expected impact

downward pressure as market prices in the modest guidance outlook

Evidence & confidence

The company raised full‑year revenue and EBITDA guidance only marginally above consensus, leading to a 6% pre‑market decline.

Market effects

Home‑care and health‑services sector may see broader scrutiny on guidance expectations.

U.S. small‑cap health‑services stocks could face short‑term pressure.

Limited; primarily affects U.S. investors focused on Aveanna and comparable providers.

Counterpoint

If guidance is viewed as a floor rather than a disappointment, the stock could rebound on the earnings beat.

Key entities

  • Aveanna Healthcare Holdings Inc.

    Home‑care provider reporting Q3 earnings and FY2026 guidance.

  • Jeff Shaner

    CEO of Aveanna Healthcare who commented on the results.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.